Patients with hidradenitis suppurativa show elevated levels of dozens of inflammatory proteins in their blood, and several of ...

OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point ...

A five-session course of transcranial magnetic stimulation (TMS) improved processing speed in people with schizophrenia, a cognitive domain that is among the most severely affected in patients, Five ...

Cardiovascular disease (CVD) became the leading cause of death in Hispanic adults in the U.S. in 2022, ahead of cancer, and researchers have been taking a closer look into this population of roughly ...

The FDA approved Dupixent (dupilumab) as a treatment for moderate-to-severe atopic dermatitis for adolescents in 2019, then for older children, ages 6 to 11, a year later, and, two years later, for ...

Kessler, a principal at Milliman, says employers need to pay attention to their claims and pharmacy benefit contracts.

National Alliance of Healthcare Purchaser Coalitions (National Alliance) has named Jenny Goins its interim president and CEO ...

GLP-1 therapies continue to materially influence drug spend, with 2025 overall trend at 8.4% versus 7.9% excluding GLP-1s, ...

As PBMs plan for 2028 rollout of the PBM transparency provisions of the Consolidated Appropriations Act of 2026 (CAA 2026) ...

Optum Rx's automated prior authorization tool, PreCheck Prior Authorization, is automating almost two-thirds of approved ...

GLP-1s now dominate market momentum, with obesity products surging from near-zero in 2022 to $55B annually and diabetes ...

FDA expands accelerated approval of oral sevabertinib for first-line HER2-mutant lung cancer, offering targeted treatment with strong response rates versus standard chemotherapy.